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Abstract
Background
Combinations of multiple fatty acids may influence cardiometabolic risk more than single
fatty acids. The association of a combination of fatty acids with incident type 2 diabetes
(T2D) has not been evaluated.
Methods and findings
We measured plasma phospholipid fatty acids by gas chromatography in 27,296 adults,
including 12,132 incident cases of T2D, over the follow-up period between baseline (1991–
1998) and 31 December 2007 in 8 European countries in EPIC-InterAct, a nested case-
cohort study. The first principal component derived by principal component analysis of 27
individual fatty acids (mole percentage) was the main exposure (subsequently called the
fatty acid pattern score [FA-pattern score]). The FA-pattern score was partly characterised
by high concentrations of linoleic acid, stearic acid, odd-chain fatty acids, and very-long-
chain saturated fatty acids and low concentrations of γ-linolenic acid, palmitic acid, and
long-chain monounsaturated fatty acids, and it explained 16.1% of the overall variability of
the 27 fatty acids. Based on country-specific Prentice-weighted Cox regression and ran-
dom-effects meta-analysis, the FA-pattern score was associated with lower incident T2D.
Comparing the top to the bottom fifth of the score, the hazard ratio of incident T2D was 0.23
(95% CI 0.19–0.29) adjusted for potential confounders and 0.37 (95% CI 0.27–0.50) further
adjusted for metabolic risk factors. The association changed little after adjustment for indi-
vidual fatty acids or fatty acid subclasses. In cross-sectional analyses relating the FA-pat-
tern score to metabolic, genetic, and dietary factors, the FA-pattern score was inversely
associated with adiposity, triglycerides, liver enzymes, C-reactive protein, a genetic score
representing insulin resistance, and dietary intakes of soft drinks and alcohol and was posi-
tively associated with high-density-lipoprotein cholesterol and intakes of polyunsaturated
fat, dietary fibre, and coffee (p < 0.05 each). Limitations include potential measurement
error in the fatty acids and other model covariates and possible residual confounding.
Conclusions
A combination of individual fatty acids, characterised by high concentrations of linoleic acid, odd-
chain fatty acids, and very long-chain fatty acids, was associated with lower incidence of T2D.
The specific fatty acid pattern may be influenced by metabolic, genetic, and dietary factors.
Author summary
Why was this study done?
• Fatty acid subclasses (e.g., saturated fatty acids or omega-6 fatty acids) and individual
fatty acids in the blood have been studied to understand the aetiology of type 2 diabetes
and as biomarkers of dietary intakes.
A fatty acid combination and incidence of type 2 diabetes
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• Existing studies suggest that different types of fatty acids are mutually correlated and are
altered together by pharmacological intervention, dietary intervention, or both.
• However, no study to our knowledge has reported whether a certain combination of dif-
ferent types of circulating individual fatty acids could be associated with the risk of type
2 diabetes.
What did the researchers do and find?
• We evaluated 27 individual fatty acids in the blood samples of adults within a large
study from 8 countries in Europe, among a reference sub-cohort sample of 15,919 adults
and among 12,132 adults who subsequently developed type 2 diabetes over a follow-up
period of 12 years on average.
• We identified a fatty acid combination that was partly represented by a combination of
high concentrations of linoleic acid (the most abundant omega-6 polyunsaturated fatty
acid), low concentrations palmitic acid (the major saturated fatty acid), and varying
concentrations of the other essential and non-essential fatty acids.
• We found that incidence of type 2 diabetes was lower by 63% on average when compar-
ing the 20% of adults with fatty acid profiles most consistent with this particular combi-
nation (e.g., high linoleic acid and low palmitic acid) with the 20% of adults with fatty
acid profiles least like this particular combination (e.g., low linoleic acid and high pal-
mitic acid).
• The combination of fatty acids was also linked to genes related to insulin resistance, car-
diometabolic risk factors, and dietary intakes of polyunsaturated fatty acids, coffee, soft
drinks, and dietary fibre.
What do these findings mean?
• A combination of fatty acids may be potentially important in the development of type 2
diabetes over and above individual fatty acids or fatty acid subclasses.
• Dietary, pharmacological, and genetic investigations are warranted to characterise the
clinical and biological implications of the combination of different types of individual
fatty acids, for example, to predict the risk of type 2 diabetes, to better understand the
aetiology of type 2 diabetes, and to consider interventions to favourably alter fatty acid
profiles.
Introduction
Fatty acids play vital roles in metabolic homeostasis, serving as precursors of signalling mole-
cules, energy sources, and constituents of membranes and functional lipids [1,2]. Reflecting
their diverse roles, fatty acids have been evaluated as markers of physiological homeostasis,
metabolic disorders, and dietary exposure in biological, clinical, and population-based
research [3–5]. For example, blood or tissue levels of omega-3 polyunsaturated fatty acids
(PUFAs) have been studied as a cardio-protective factor in biochemical and clinical research
A fatty acid combination and incidence of type 2 diabetes
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and as a biomarker of dietary consumption of omega-3 PUFAs in epidemiological research
[1,2,4–6]. However, research to date has largely evaluated individual fatty acids or single sub-
groups of fatty acids, rather than combinations of fatty acids, in terms of mechanism or as
potential biomarkers.
Combinations of fatty acids may have aetiological and clinical implications for metabolic
diseases including type 2 diabetes (T2D). Insulin resistance and pancreatic lipotoxicity have
been found to be influenced by multiple fatty acids. For example, palmitic acid (16:0) induces
lipotoxicity, and unsaturated fatty acids may prevent it [7–9]. Pharmacological and nutritional
research also warrant considering multiple fatty acids together. Interventions of lipid-lowering
drugs or dietary carbohydrates or fats, for example, alter blood concentrations of individual
PUFAs and saturated fatty acids (SFAs) jointly [3,9–11]. These findings support the notion
that combinations of fatty acids are important to study in relation to the aetiology of T2D and
to predict T2D risk.
A few epidemiological studies have identified combinations of circulating or tissue fatty
acids associated with adiposity, hypertension, and risks of metabolic syndrome and cardiovas-
cular diseases using a statistical pattern-recognition approach [12–15]. These studies have
indicated potential biological and clinical importance of combinations over and above that of
individual fatty acids. However, a combination of fatty acids has never been evaluated as a
potential risk factor for incident T2D. Thus, we first aimed to identify 1 or more combinations
of phospholipid fatty acids that explained variability in multiple fatty acid concentrations,
using epidemiological data from the European Prospective Investigation into Cancer and
Nutrition (EPIC)–InterAct study. Then, focussing on the single combination of fatty acids that
explained the greatest variability, we tested the hypothesis that the combination is associated
with the incidence of T2D. To provide mechanistic insights, we further examined the associa-
tion of this combination of fatty acids with metabolic risk factors, genetic predisposition to
obesity and insulin resistance, and dietary intakes in EPIC-InterAct. For metabolic and dietary
factors, external validation was performed by evaluating data of the US National Health and
Nutrition Examination Survey (NHANES).
Methods
Study population
We conducted this work as a substudy of the fatty acid project in EPIC-InterAct to explore a
combination of fatty acids to add to our previous work on individual fatty acids and subclasses
(S1 Protocol) [16,17]. EPIC-InterAct is a prospective study nested within 8 European countries
of the EPIC study (Denmark, France, German, Italy, Netherlands, Spain, Sweden, and UK)
[16,18]. In EPIC-InterAct, the case-cohort design was adopted to combine the advantages of a
prospective design with the efficiency of a case-control design [19]. From the 340,234 adults
with 3.99 million person-years of follow-up of the EPIC study, EPIC-InterAct (1) randomly
selected 16,835 adults (‘sub-cohort’) and (2) identified 12,403 incident cases of T2D occurring
by 31 December 2007; the identified cases included 778 cases in the sub-cohort by design (S1
Fig) [16,18]. All participants gave written informed consent. The study was approved by local
ethics committees and the institutional review board of the International Agency for Research
on Cancer [18].
The current study included 15,919 adults from the sub-cohort—after excluding 916 meeting
1 or more exclusion criteria: prevalent diabetes (n = 548), missing information on fatty acids
(n = 156), missing information on incident T2D (n = 129), and post-censoring T2D (n = 4)—
and included 12,132 incident T2D cases, after excluding 271 adults missing information on
A fatty acid combination and incidence of type 2 diabetes
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fatty acids (S1 Fig). In summary, we evaluated 27,296 adults in this study (12,132 cases, includ-
ing 755 cases from the sub-cohort; and 15,919 adults from the sub-cohort).
Ascertainment of type 2 diabetes
Prevalent diabetes cases (excluded from the study) were identified by baseline self-report of a
diagnosis, physician’s diagnosis, anti-diabetic drug use, or other evidence of T2D before the
baseline date in EPIC-InterAct [18]. Incident T2D was ascertained from multiple information
sources reviewed by each participating centre [18]: self-report, linkage to primary-care regis-
ters, secondary-care registers, medication use (drug registers), hospital admissions, and mor-
tality data. Information from any follow-up visit or external evidence with a date later than the
baseline visit was used. In Denmark and Sweden, incident cases were identified via local and
national diabetes and pharmaceutical registers, and hence all ascertained cases were consid-
ered to be verified. Follow-up was to the date of diagnosis, 31 December 2007, or the date of
death, whichever occurred earliest.
Assessment of fatty acids and other variables
We evaluated relative concentrations of 27 individual fatty acids expressed as mole percentage
of total plasma phospholipid fatty acids (Table 1), as previously described (S1 Text) [16,20].
These measurements were masked to case status. Thirty-seven fatty acids of plasma phospho-
lipids were quantified by gas chromatography [20]. In the current analysis, 10 fatty acids were
excluded because their relative concentrations were<0.05% on average. Coefficients of varia-
tion of the 27 fatty acids ranged from 1.9% to 4.6% [20].
At baseline, weight, height, and waist circumference were measured directly in every centre.
Waist circumference was not measured in Umea, Sweden (n = 1,845) [18]. Sociodemographic
factors, smoking status, and medical history were assessed by a questionnaire for general
health. Physical activity was assessed by a questionnaire validated previously [21]. Dietary vari-
ables were derived centrally based on food frequency questionnaires or diet histories standard-
ised in each cohort [22,23]. Using blood samples stored at −196˚C (or −150˚C in Denmark),
biochemical assays were performed at Stichting Ingenhousz Laboratory, Etten-Leur, Nether-
lands, for glucose, triglycerides, high-density lipoprotein cholesterol (HDL-C), triglycerides,
high-sensitivity C-reactive protein (hsCRP), and proteins related to hepatic function—alanine
transaminase (ALT), γ-glutamyl transferase (GGT), and aspartate transaminase (AST)—as the
liver is the major organ metabolising fatty acids.
Genetic information became available in 22,179 adults with fatty acid data, assayed with
Illumina Human660W-Quad BeadChip (Illumina, Little Chesterford, UK; n = 9,166) and
MetaboChip (Illumina; n = 13,013) [24]. Using these data, we conducted post hoc analyses to
examine whether genetic predisposition to metabolic risk was associated with the FA-pattern
score. We calculated weighted genetic risk scores for body mass index (BMI) (n loci = 97) [25]
and for insulin resistance (n loci = 10) [24] using published measures of genome-wide associa-
tions (S1 Text).
Derivation of fatty acid pattern score
Principal component analysis (PCA) was performed in the sub-cohort (n = 15,919) to combine
multiple fatty acids (Table 1) together in a way to explain as much variation of those fatty acids
as possible. Sampling weights were applied so that each of the 8 countries equally contributed
to the PCA. Eigenvalues divided by 27 were assessed as percent of variance explained.
Principal components were inferred as representing fatty acid patterns. The pattern matrix
from PCA was then used to calculate the scores, referred to as FA-pattern scores, among the
A fatty acid combination and incidence of type 2 diabetes
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rest of the study population (incident T2D cases not in the sub-cohort, Fig 1) and was also
applied to quality control samples (n = 860) to assess the contribution of any batch effects [20].
We chose to focus on the first principal component for further aetiological analyses to provide
potential biological implications of this single combination of fatty acids. This enabled us to
Table 1. Relative concentrations of plasma phospholipid fatty acids and their correlations with the identified fatty acid pattern score: EPIC-Inter-
Act sub-cohort (n = 15,919).
Individual FA* Name Percent of total phospholipid FAs Correlation with the FA-pattern score†
Median 10th and 90th percentiles
Long-chain saturated FA
14:0 Myristic acid 0.38 0.26, 0.53 −0.34
16:0 Palmitic acid 30.1 28.2, 32.4 −0.51
18:0 Stearic acid 14.1 12.4, 15.8 0.36
Odd-chain saturated FA
15:0 Pentadecanoic acid 0.22 0.15, 0.31 0.27
17:0 Heptadecanoic acid 0.42 0.31, 0.53 0.57
Very-long-chain saturated FA
20:0 Arachidic acid 0.13 0.10, 0.18 0.55
22:0 Behenic acid 0.23 0.17, 0.32 0.69
23:0 Tricosanoic acid 0.11 0.07, 0.16 0.49
24:0 Lignoceric acid 0.22 0.17, 0.30 0.59
Monounsaturated FA
16:1 Palmitoleic acid 0.47 0.29, 0.79 −0.75
18:1n-9 Oleic acid 9.6 7.7, 11.9 −0.50
Very-long-chain monounsaturated FA
20:1 Gondoic acid 0.25 0.17, 0.34 −0.04
24:1 Nervonic acid 0.34 0.25, 0.46 0.42
Omega-6 PUFA
18:2n-6 Linoleic acid 22.5 18.4, 26.6 0.45
18:3n-6 γ-linolenic acid 0.07 0.02, 0.14 −0.51
20:3n-6 Dihomo-γ-linolenic acid 3.1 2.2, 4.2 −0.38
20:4n-6 Arachidonic acid 9.2 7.0, 11.7 −0.17
Omega-3 PUFA
18:3n-3 α-linolenic acid 0.28 0.15, 0.54 −0.04
20:5n-3 Eicosapentaenoic acid 1.02 0.52, 2.13 0.03
22:5n-3 Docosapentaenoic acid 0.92 0.62, 1.22 0.02
22:6n-3 Docosahexaenoic acid 4.1 2.7, 5.9 0.23
Trans unsaturated FA
Trans 18:1 Elaidic acid 0.21 0.10, 0.52 0.20
Trans 18:2 Trans linoleic acid 0.07 0.04, 0.09 0.18
Other
17:1 Heptadecenoic acid 0.06 0.00, 0.13 −0.13
20:2 Eicosadienoic acid 0.38 0.30, 0.47 −0.08
22:4 Adrenic acid 0.28 0.20, 0.39 −0.39
22:5n-6 Osbond acid 0.19 0.11, 0.31 −0.39
*FAs are subclassified according to generic classification.
†The first principal component (FA-pattern score) derived by principal component analysis of the 27 individual fatty acids (n = 15,919), used as the main
exposure variable in this study. Coefficients to calculate the FA-pattern score are presented in S5 Table.
FA, fatty acid; FA-pattern score, fatty acid pattern score; PUFA, polyunsaturated fatty acid.
https://doi.org/10.1371/journal.pmed.1002409.t001
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Fig 1. Principal components and clusters of 27 fatty acids in the EPIC-InterAct sub-cohort (n = 15,919). Top: The proportion of total
variance of 27 fatty acids explained by each principal component. Bottom: Hierarchical cluster tree on the left and factor loadings (measures of
contributions of fatty acids to principal components) on the right.
https://doi.org/10.1371/journal.pmed.1002409.g001
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conduct and report a detailed investigation into the associations of this combination with T2D
incidence and metabolic, dietary, and genetic variables, and their biological implications; it
also removed the need for subjective decisions about how many components to derive, which
matrix rotation method to use, and how to account for multiple testing [26].
Statistical analysis
All analyses were performed using Stata (StataCorp, College Station, Texas, US), with αtwo-sided =
0.05. For descriptive purposes, a hierarchical cluster tree was generated to visually assess correla-
tion between fatty acids [27]. Pearson correlation coefficients between fatty acids were also calcu-
lated. The strength of association of the FA-pattern score with incident T2D was evaluated by
estimating hazard ratios (HRs) and 95% CIs from Prentice-weighted Cox regression, with age as
the underlying timescale [19]. The estimates were obtained in each country and pooled by ran-
dom-effects meta-analysis [28] for quintiles specific to the sub-cohort, for a continuous term per
interdecile range (the difference between the 90th and 10th percentiles of the distribution), and
for cubic-spline terms to test non-linear associations [29]. We additionally computed a 95% pre-
dicted interval for the primary results by combining random-effects variation (tau2) and varia-
tion of the main estimate [28].
The models included potential confounders, including demographics, prevalent heart dis-
ease and stroke, medication use, smoking status, physical activity, and dietary factors (con-
sumption of alcohol, soft drinks, dietary fibre, fruits, vegetables, and processed meats), that are
associated with cardiometabolic health in general. We also adjusted for BMI, waist circumfer-
ence, glucose, lipids, hsCRP, and liver enzymes to examine their influence on the associations
of interest. Potential confounding by genetic predisposition for greater BMI and insulin resis-
tance was also assessed.
In pre-specified analyses, we examined whether observed associations varied by baseline
age, sex, and BMI, testing an interaction term for each factor and the FA-pattern score in
regression analysis. Effect modification by blood triglycerides, use of lipid-lowering drugs (yes
or no), and alcohol consumption (consumer or non-consumer) was also tested post hoc
because of the association of triglycerides with the FA-pattern score (r = −0.29) and possible
effects of lipid-lowering drugs and alcohol on de novo lipogenesis. Missing covariates were
imputed by country, using multiple imputation by chained equations with variables for the
FA-pattern score, covariates, survival time, and case status [30]. We report results from single
imputation, because between-imputation variability was <0.2% of total variability in multiple
imputation (20 datasets); we performed sensitivity analysis using multiple imputation and
complete-case analysis.
As a sensitivity analysis to assess whether HR varied over the follow-up time by reverse cau-
sation, stratified analysis was performed by splitting follow-up time at 7 years after baseline
and by censoring any events occurring within the first 2 years as non-cases. We additionally
evaluated the stability of our findings: examining the consistency of a main finding for the sin-
gle principal component when PCA was performed after Box–Cox transformation, improving
normality of distribution of all fatty acid variables. We also examined whether or not the main
result was driven by single fatty acids or fatty acid subclasses through 2 approaches: adjusting
models for single fatty acids and subclasses separately, and repeating the analysis after PCA of
fatty acids excluding each of the 27 fatty acids or subclasses one at a time. We performed inter-
nal cross-validation [31]: First, we re-derived the FA-pattern score in a subset selected by
country, age, sex, and BMI (test set); second, we applied the scoring matrix to another subset
(validation set) to derive the FA-pattern score, and then we examined the associations of the
independently derived score with incident T2D.
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Analysis of metabolic, genetic, and dietary factors
To investigate potential mechanisms for the association of the FA-pattern score with incident
T2D, we estimated cross-sectional associations of the FA-pattern score with each of selected
metabolic risk factors (BMI, waist circumference, lipids, glucose, hsCRP, and liver enzymes)
using linear regression. Additionally, modified Poisson regression [32] was used to examine
the cross-sectional association of the FA-pattern score with prevalence of hepatic steatosis
defined as ALT greater than cut-points previously validated against ultrasound (30 U/l for
men, 19 U/l for women) [33]. We further fitted linear regression to assess whether genetic risk
scores for BMI and for insulin resistance (independent variables) could explain variability in
the FA-pattern score (dependent variable). These regression models statistically adjusted for
age and the other covariates used for longitudinal analyses.
We also evaluated dietary factors as potential lifestyle determinants of the FA-pattern score.
Multivariable-adjusted linear models included dietary determinants as independent variables
and the FA-pattern score (scaled to 1 standard deviation) as a dependent variable. This analysis
evaluated major macronutrient and fibre intakes (nutrient-based analysis) and 18 selected
foods or beverages (food-based analysis).
Assessment of external validity
Recognising the risk of false-positive findings based on our data-driven approach, we con-
ducted post hoc assessment of the external validity of the FA-pattern score derived in EPIC-In-
terAct, using cross-sectional data from NHANES 2003–2004 (n = 1,566) on total plasma fatty
acids, metabolic factors, dietary factors, and potential confounders. Using the scoring matrix
derived from EPIC-InterAct, we calculated the FA-pattern score in NHANES (S2 Text) [15].
Using linear regression adjusting for potential confounders, replication analyses were per-
formed (S3 Text). In dietary analyses, 18 dietary items were first assessed in EPIC-InterAct
with backward variable selection (p = 0.2 as a cutoff, additionally for the purpose of adjustment
[34]) to identify which dietary variables predicted the FA-pattern score together. Then we
tested selected dietary factors in NHANES for external validation (S3 Text) in linear regression
adjusting for potential confounders and including the same dietary variables. The 18 food
groups first tested in EPIC-InterAct were selected by possible biology of diets, fatty acid pro-
files, and T2D, and evaluated both individually and simultaneously.
Results
The first component derived by PCA explained 16.1% of the variation of 27 fatty acids, and 6
to 10 components explained more variation than 1 fatty acid could explain (>3.7% of total;
‘eigenvalue’ > 1.0) (Fig 1). The first 4 components had loading values (e.g., >0.6 or <−0.6) in
multiple fatty acid classes. Selected to gain insight into the biological importance of a combina-
tion of fatty acids, the first component reflected relationships between fatty acids varying in
chain length and degree of unsaturation, including fatty acids that can be synthesised endoge-
nously and those derived from dietary consumption (Table 1; Fig 1). A similar pattern was
identified in cluster analysis, as fatty acids adjacent in the tree had similar loading values (Fig
1). Major contributors (correlation coefficients r> 0.5 or r< −0.5) were palmitic acid (16:0,
r = −0.51), palmitoleic acid (16:1, r = −0.75), and γ-linolenic acid (18:3n-6, r = −0.51). Hepta-
decanoic acid (17:0) and very-long-chain SFAs (VLSFAs) with 20 or more carbons had posi-
tive contributions (r = 0.5–0.7), but their relative concentrations were low (<1% of total).
While linoleic acid (18:2n-6) had a positive contribution (r = 0.45), the other PUFAs, and
trans unsaturated fatty acids had lower contributions (−0.25< r< 0.25) (Fig 1). The coeffi-
cient of variation of the FA-pattern score was 6.0% based on the quality control samples.
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Adults with higher FA-pattern score were more likely to be women, non-smokers, non-
users of lipid-lowering drugs, and those with generally healthier profiles of metabolic risk fac-
tors, while there was no significant relationship with age or education (S1 Table). Covariates
had missing values in<5% of adults, except 49.9% for family history of diabetes, which was
not assessed in 12 of the 26 study centres (S2 Table). Where it was assessed, 24.5% of partici-
pants had missing information.
Association of the fatty acid pattern score with incidence of type 2
diabetes
In the longitudinal analysis of 12,132 cases per 190,148.9 person-years (11.9 y of follow-up per
person on average), the FA-pattern score was strongly associated with incident T2D. Adjusted for
sociodemographic variables, dietary factors, and medical history, the HR (95% CI) of T2D com-
paring the top to the bottom fifth of the FA-pattern score was 0.23 (0.19–0.29) (p trend< 0.001)
(Table 2). The association persisted after adjustment for BMI (HR 0.32; 95% CI 0.25–0.40) and
for triglycerides and HDL-C (0.37; 95% CI 0.27–0.50). Results changed little when additionally
adjusted for concentrations of random glucose, hsCRP, hepatic enzymes, other dietary factors,
family history of T2D, and genetic risk scores for obesity and insulin resistance (S3 Table). The
association varied across the 8 countries (Fig 2; I2 = 88%); this variation was partly explained by
country-specific mean ages and percentage of men (p< 0.05 each), although an inverse associa-
tion was observed in all countries.
There was no evidence of effect modification by baseline age, sex, BMI, triglycerides, lipid-
lowering drug use, or alcohol consumption (p interaction > 0.1 each). The main result was sta-
ble in sensitivity analyses that explored the influence of imputation, duration of follow-up, and
normality of distribution (S3 Table). In analyses adjusting for individual fatty acid variables
(S2 Fig), adjustment for 17:0 attenuated the estimates to the greatest extent among the fatty
acid variables we evaluated, shifting the HR (95% CI) of 0.38 (0.30–0.47) to 0.53 (0.42–0.67),
but with the association remaining significant. Cross-validation analysis confirmed the stabil-
ity of the findings (S4 Table). For instance, when the FA-pattern score was derived in 7
Table 2. Association of the fatty acid pattern score with incidence of type 2 diabetes: EPIC -InterAct (n = 27,296).
Model Quintile of the fatty acid pattern score* P trend
I II III IV V
Number of cases 4,277 2,910 2,113 1,587 1,245
Incidence rate per 100,000 person-years† 679 476 349 283 219 <0.001
Pooled hazard ratio (95% CI)‡
Multivariable-adjusted 1.0 (reference) 0.68 (0.62–0.75) 0.46 (0.40–0.53) 0.32 (0.28–0.35) 0.23 (0.19–0.29) <0.001
+ Body mass index 1.0 (reference) 0.75 (0.69–0.82) 0.53 (0.46–0.62) 0.40 (0.35–0.46) 0.32 (0.25–0.40) <0.001
+ Triglycerides and HDL-C 1.0 (reference) 0.78 (0.70–0.86) 0.56 (0.46–0.68) 0.44 (0.36–0.53) 0.37 (0.27–0.50) <0.001
*Five categories were obtained by quintiles of the fatty acid pattern score in EPIC-InterAct. Each participant was assigned a fatty acid pattern score
(mean = 0, standard deviation = 1) by principal component analysis using 27 individual fatty acids.
†Incidence was calculated in the random sub-cohort (n = 15,919).
‡Multivariable-adjusted Prentice-weighted Cox regression models. The first model adjusted for recruitment centre (2 to 6 categories in each country), age as
covariate, and underlying timescale, sex, education history, smoking status, alcohol consumption, dietary factors (dietary fibre, fruits, vegetables,
processed meats, soft drinks), physical activity, menopause status, hormone replacement use, and prevalent diseases (myocardial infarction or angina,
stroke, hypertension, and dyslipidaemia). Pooled results from 8 countries were obtained by random-effects meta-analysis. Hazard ratios (95% CIs) per
interdecile range in the 3 models were 0.28 (0.24–0.33), 0.33 (0.28–0.40), and 0.38 (0.30–0.47), respectively.
HDL-C, high-density lipoprotein cholesterol.
https://doi.org/10.1371/journal.pmed.1002409.t002
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countries, not 8, and the scoring algorithm was applied to adults in the 1 country excluded, the
summary HR (95% CI) in the most adjusted model was 0.40 (0.34–0.50).
Association of the fatty acid pattern score with metabolic, genetic, and
dietary factors
In both EPIC-InterAct and NHANES (see S5 Table for scoring coefficients), the FA-pattern
score was associated with metabolic risk factors in the direction consistent with the above find-
ings for incident T2D. Inverse associations were seen with BMI, triglycerides, glucose, hsCRP,
ALT, AST, GGT, and the likelihood of having hepatic steatosis (p< 0.001 each) (Table 3). A
significant positive association with HDL-C was observed in NHANES (p< 0.001), but not in
EPIC-InterAct (p = 0.7).
In genetic analyses (EPIC-InterAct only), a gene score related to higher BMI was not signif-
icantly associated with the FA-pattern score: +0.1% of SD of the FA-pattern score (95% CI
−0.6% to +1.7%; p = 0.3) per interdecile range of the genetic score. A gene score related to
higher insulin resistance was significantly associated with lower FA-pattern score: −1.9% of
SD (95% CI −3.4% to −0.4%; p = 0.02).
In dietary analyses in EPIC-InterAct and NHANES, higher intakes of PUFAs and fibre were
associated with higher FA-pattern score in both cohorts (Fig 3). For example, replacing carbo-
hydrates with PUFAs in the diet by an amount equivalent to 5% of total energy was positively
associated with the FA-pattern score (0.43 SD of the score, 95% CI 0.30–0.57) in EPIC-InterAct
and 0.21 (95% CI 0.11–0.32) in NHANES. In food-based analysis of EPIC-InterAct, the FA-pat-
tern score was significantly related to higher intakes of fish, margarine, and coffee and lower
intakes of soft drinks and alcoholic beverages (p< 0.05 each) when assessed individually (S3
Fig) and simultaneously (Fig 3). In NHANES, findings from EPIC-InterAct for soft drinks, cof-
fee, and alcohol were replicated (p< 0.04) (Fig 3).
Fig 2. Prospective associations of the fatty acid pattern score with incident diabetes in 8 countries: EPIC-InterAct (n = 27,296). Left: Hazard
ratios (HRs) per country-specific range of 10th to 90th percentiles (p for heterogeneity by age and sex = 0.005 and 0.02, respectively), and pooled by
random-effects meta-analysis. The diamond and error bars of the pooled estimate represent the 95% confidence interval and predicted interval (0.20 to
0.74), respectively. Right: HR based on quintiles and restricted cubic spline (p non-linearity = 0.001) (solid line). Error bars in both panels, and dotted lines
in the right panel, indicate the 95% confidence intervals of HRs, and the shaded area in the right panel is the predicted interval. All analyses adjusted for
covariates as in the most adjusted model in Table 2.
https://doi.org/10.1371/journal.pmed.1002409.g002
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Discussion
We evaluated fatty acid profiles among adults in 8 European countries and derived a FA-pat-
tern score that represents a combination of both essential and non-essential fatty acids and
that is characterised by high relative concentrations of linoleic acid (18:2n-6), stearic acid
(18:0), odd-chain SFAs, and VLSFAs (20 carbons), and by low relative concentrations of γ-
linolenic acid (18:3n-6), monounsaturated fatty acids (MUFAs), and long-chain SFAs (14:0
and 16:0). The unique combination was associated with dietary, metabolic, and genetic factors,
and prospectively associated with a lower incidence of T2D. Comparing the top fifth to the
bottom fifth of the FA-pattern score, T2D incidence was lower by approximately 60%. This
robust association with incident T2D was independent of established risk factors and also any
single fatty acids or fatty acid subclasses. These findings support the hypothesis that a combi-
nation of multiple fatty acids is an important marker for the development of T2D above and
beyond the roles of single types of fatty acids. The combination of essential and non-essential
fatty acids is of strong interest for further clinical or population-based investigations to predict
T2D risk, identify interventional agents for T2D prevention, and better understand the aetiol-
ogy of T2D.
The combination of fatty acids contributing to the identified FA-pattern score fits with
known mechanisms involving the de novo lipogenesis (DNL) pathway. In DNL, fatty acids
including 14:0, 16:0, 16:1n-7, and 18:1n-9 are synthesised endogenously, where stearoyl-CoA
desaturase (SCD) converts 16:0 to 16:1n-7 as a rate-limiting step of fatty acid synthesis. The
inverse correlation of 18:2n-6 with these fatty acids may reflect its role as a ligand of peroxi-
some proliferator-activated receptor α (PPARα) [2,5]. PPARα down-regulates SCD and
ELOVL (elongation of very-long-chain fatty acid) enzymes, explaining the observed inverse
correlation of 18:2n-6 with MUFAs, 16:0, 18:3n-6, and other n-6 PUFAs [2]. An exception of
PPARα’s action is activation of ELOVL3, which leads to synthesis of VLSFAs in the adipose
tissue [35] and supports the observed associations between 18:2n-6, 18:0, and VLSFAs. While
our findings are in line with the benefit of dietary PUFAs (predominantly 18:2n-6), other
major PUFAs (e.g., omega-3 PUFA) contributed little to the primary fatty acid combination.
Table 3. Associations of the fatty acid pattern score with metabolic factors in EPIC-InterAct and with metabolic factors in the US NHANES 2003–
2004.
Metabolic factor EPIC-InterAct (n = 15,919) NHANES (n = 1,566)
Body mass index, kg/m2 −1.2 (−1.5, −0.9) −2.3 (−3.0, −1.7)
Triglycerides, mmol/l −0.6 (−0.7, −0.5) −1.9 (−2.2, −1.6)
HDL-C, mmol/l 0.00 (−0.03, 0.02) 0.26 (0.21, 0.31)
Glucose, mmol/l −0.24 (−0.29, −0.19) −0.26 (−0.37, −0.15)
Alanine transaminase, U/l −3.2 (−4.2, −2.2) −3.7 (−6.1, −1.3)
Aspartate transaminase, U/l −3.1 (−4.1, −2.1) −5.6 (−8.1, −3.2)
γ-glutamyl transferase, U/l −15.3 (−20.8, −9.9) −13.5 (−18.5, −8.4)
C-reactive protein, nmol/l −0.43 (−0.61, −0.26) −0.15 (−0.26, −0.05)
High risk of hepatic steatosis, percent prevalence* −28% (−32%, −23%) −16% (−30%, −1%)
For metabolic risk factors, values are difference (95% confidence interval) in each metabolic factor per interdecile range of fatty acid pattern score. Linear
regression analysis was performed, adjusting for potential confounders and body mass index (for metabolic factors except body mass index) (see S3 Text
for details). All differences were significant, p < 0.02, with exception of HDL-C in EPIC-InterAct (p = 0.7).
*Prevalence ratio was estimated for the likelihood of having hepatic steatosis (alanine transaminase > 30 U/l for men and >19 U/l for women [33]) (i.e.,
relative difference in prevalence).
HDL-C, high-density lipoprotein cholesterol; NHANES, National Health and Nutrition Examination Survey.
https://doi.org/10.1371/journal.pmed.1002409.t003
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This could reflect their diverse roles in eicosanoid pathways and pro- and anti-inflammatory
pathways, and their associations with dietary intakes (e.g., fish) independent of DNL-driving
dietary factors [5].
These suggested mechanisms are linked to the development of T2D. Activation of PPARα
suppresses hepatic DNL and pro-inflammatory pathways that lead to insulin resistance, dysli-
pidaemia, and fatty liver [2,5,36]. In an experimental setting, for example, PPARα knock-out
mice developed fatty liver exhibiting overt hepatic lipogenesis [37]. Main products of DNL
include 16:0 and diacylglycerols that cause a pro-inflammatory response, endoplasmic reticu-
lum stress, and insulin resistance [1,38]. Thus, our analysis yielded a combination of multiple
fatty acids that may represent biological pathways related to insulin resistance, inflammatory
responses, and T2D risk. This was confirmed with the observed associations of FA-pattern
score with metabolic risk factors in an expected direction and the association of FA-pattern
score with genetic predisposition to insulin resistance. Associations of gene variants with fatty
acids and with incident T2D cannot be confounded by long-term lifestyle characteristics.
Fig 3. Associations of dietary factors with the fatty acid pattern score in EPIC-InterAct (1991–1998,
n = 15,566) and the US National Health and Nutrition Examination Survey (2003–2004, n = 1,500). Error
bars are 95% confidence intervals. In analysis for macronutrients, analysis estimated potential effects of
replacing carbohydrate (CHO) intakes with intakes of polyunsaturated fatty acid (PUFA), monounsaturated
fatty acid (MUFA), saturated fatty acid (SFA), and protein by the amount of 5% of total caloric intake. Dietary
factors were scaled for interpretability: sv, serving; oz., ounce (28.8 g); tbls, tablespoon. *Alcoholic drinks
were examined as grams of ethanol.
https://doi.org/10.1371/journal.pmed.1002409.g003
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Therefore, the specific gene variants, the identified combination of fatty acids, and the risk of
T2D are likely to be on the same causal pathway, warranting future research to elucidate how
insulin resistance specifically alters fatty acid profiles or vice versa.
Our analysis and prior studies derived a similar combination of fatty acids [12–15], but no
previous studies to our knowledge evaluated T2D incidence as an outcome. Past studies used
different methods and examined varied numbers of fatty acids (10 to 42) of phospholipids
[15], cholesteryl esters [12,15], plasma [13], or adipose tissue [14]. Despite the differences, all
of the studies reported a combination of fatty acids partly driven by higher levels of 18:2n6
with lower 16:0, which could reflect activity of DNL [39]. These combinations were found to
be associated with lower blood pressure, greater endothelial function, less weight gain over
time, or lower risk of metabolic syndrome [12–14]. In contrast, an association with ischaemic
heart disease or stroke was not significant [15]. The inconsistency depending on outcome is
predictable as DNL could promote insulin resistance, but suppress atherosclerosis [36]. Statins
and other lipid-lowering drugs also alter fatty acid profiles [10] and have divergent effects on
heart disease and T2D [40]. Thus, a fatty acid pattern can be a future focus of investigations of
cardiometabolic diseases and related interventions.
The association of the FA-pattern score with incident T2D was not fully explained by any
single fatty acid, but was partly attenuated by adjustment for odd-chain SFAs and VLSFAs.
These SFAs are associated with lower risk of cardiometabolic diseases [16,41,42], while their
biological roles remains understudied. High phospholipid VLSFAs may reflect high activity of
PPARα, which leads to VLSFA synthesis and less insulin resistance, apoptotic cell death, and
pancreatic dysfunction [41,43]. Blood odd-chain SFAs may partly reflect dairy consumption
[3,44], gut microbiota [45], or endogenous synthesis through α-oxidation [46], and thus any
correlates to those factors could explain our findings. Evidence for these mechanisms and rela-
tionships with other fatty acids remains scarce and deserves further investigation.
Dietary correlates with the combination of fatty acids deserve discussion, as they were repli-
cated in EPIC-InterAct and NHANES: alcohol and soft drinks as negative correlates, and cof-
fee, fibre, and PUFAs as positive correlates. The finding for alcohol consumption is likely to
reflect its lipogenic effect, a risk factor for liver cirrhosis and T2D [47]. Regarding coffee con-
sumption, polyphenols may deactivate DNL [48] and lower triglyceride levels and T2D risk
[49–51]. Increased PUFA intake (predominantly n-6 PUFAs) could increase insulin sensitivity
as well as lower DNL [2,5,52]. Our findings for soft drinks and fibre may also reflect their gly-
caemic and anti-glycaemic effects, respectively, as a high glycaemic effect leads to insulin secre-
tion and DNL [2,53].
Strengths of this work include the standardised assay of fatty acid profiles in an EPIC-Inter-
Act population with geographic diversity; the large study size (to our knowledge by far the
largest among studies of fatty acid biomarkers), allowing various sensitivity analyses; and the
generalisability of our findings, strengthened by our findings across 8 European countries and
the US NHANES. By focussing on a single combination of fatty acids, we were able to report
details of its association with incident T2D and metabolic, genetic, and dietary factors. How-
ever, this also limited our investigation of other fatty acid patterns, in particular in relation to
omega-3 fatty acids. Other limitations include possible residual confounding by factors
unmeasured or measured imprecisely, although we adjusted for many covariates including
major risk factors for T2D. Whether or not the combination of fatty acids itself caused the
T2D onset remains unestablished. Possible exposure misclassification due to single fatty acid
measurements and possible outcome misclassification were limitations, but likely to be inde-
pendent of T2D case status and fatty acid profiles, respectively. We found no strong reason to
think that these limitations would alter the overall conclusions. Lastly, the generalisability of
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our findings might be limited to high-income Western populations, and fatty acid patterns in
other populations with diverse genetic backgrounds and dietary patterns are of future interest.
In conclusion, we identified a combination of plasma phospholipid fatty acids characterised
by high relative concentrations of 18:2n-6, VLSFAs, and odd-chain SFAs and low relative con-
centrations of long-chain SFAs and MUFAs, some of which are synthesised endogenously.
This particular profile was associated with a 3-fold lower relative risk of incident T2D in Euro-
pean populations after adjustment for confounding. While both genes and diet were linked to
the FA-pattern score, association of the FA-pattern score with T2D was independent of estab-
lished risk factors for T2D and not driven by individual fatty acids. These findings highlight
that multiple fatty acids are jointly related to the development of T2D. The combination of
fatty acids warrants further investigation of its determinants and potential application as a
marker of metabolic characteristics.
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